Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  18 (2024)
Volume  17 (2023)
Volume  16 (2022)
Volume  15 (2021)
Volume  14 (2020)
Volume  13 (2019)
Volume  12 (2018)
Volume  11 (2017)
Volume  10 (2016)
Volume  9 (2015)
Volume  8 (2014)
Volume  7 (2013)
Volume  6 (2012)
Volume  5 (2011)
Volume  4 (2010)
Volume  3 (2009)
Volume  2 (2008)
Volume  1 (2007)
Related articles

VOLUME 12 , ISSUE 3 ( July-September, 2018 ) > List of Articles

REVIEW ARTICLE

Screening for Ovarian Cancer by Different Modes of Transvaginal Sonography

Matija Prka, Asim Kurjak

Keywords : 3D power Doppler, Early detection, Malignant ovarian masses, Screening

Citation Information : Prka M, Kurjak A. Screening for Ovarian Cancer by Different Modes of Transvaginal Sonography. Donald School J Ultrasound Obstet Gynecol 2018; 12 (3):186-196.

DOI: 10.5005/jp-journals-10009-1570

License: CC BY-NC 4.0

Published Online: 01-12-2009

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Studies indicate that 3D power Doppler imaging can improve the ability to differentiate benign from malignant ovarian masses, increasing significantly specificity and positive predictive value (PPV) in ovarian cancer detection. Therefore, the problem of low PPV in ultrasound-only strategies may be solved by introducing new 3D ultrasound technologies, used together in a secondary screening procedure. The possible role of 3D ultrasound and 3D power Doppler imaging in the early and accurate detection of ovarian cancer is under evaluation through Zagreb Ovarian Cancer Screening Trial.

PDF Share
  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
  2. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS, Sideri M, Pecorelli S. Carcinoma of the ovary. In: 24th Volume of the FIGO Annual Report on the Results of Treatment in Gynecological Cancer. J Epidemiol Biostat 2001;6:107-138.
  3. Kirwan JMJ, Tincello DG, Herod JJO, Frost O, Kingston RE. Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit. BMJ 2002; 324:148-151.
  4. Paley PJ. Screening for the major malignancies affecting women: Current guidelines. Am J Obstet Gynecol 2001;184: 1021-1030.
  5. Urban N. Screening for ovarian cancer. BMJ 1999; 319: 1317-18.
  6. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynecol 1998;105:1136-1147.
  7. van Nagell JR, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-356.
  8. Hayashi H, Yaginuma Y, Kitamura S, Saitou Y, Miyamoto T, Komori H, Wada K, Ishikawa M. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol Obstet Invest 1999;47:58-64.
  9. Tabor A, Jensen FR, Bock JE, Hogdall CK. Feasibility study of a randomised trial of ovarian cancer screening. J Med Screen 1994;1:215-219.
  10. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989;299:1363-1367.
  11. Goswamy RK, Campbell S, Whitehead MI. Screening for ovarian cancer. Clin Obstet Gynecol 1983;10:621-643.
  12. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995;76:1214-1218.
  13. Kurjak A, Shalan H, Kupesic S, Kosuta D, Sosic A, Benic S, Ilijas M, Jukic S, Predanic M. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994; 13:295-301.
  14. Schulman H, Conway C, Zalud I, Farmakides G, Haley J, Cassata M. Prevalence in a volunteer population of pelvic cancer detected with transvaginal ultrasound and color flow Doppler. Ultrasound Obstet Gynecol 1994;4:414-420.
  15. Sato S, Yokoyama Y, Sakamoto T, Futagami M, Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000;89:582-588.
  16. Parkes CA, Smith D, Wald NJ, Bourne TH. Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen 1994;1:209-214.
  17. Holbert TR. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Am J Obstet Gynecol 1994;170:1699-1703.
  18. Einhorn N, Sjovall P, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80: 14-18.
  19. Jacobs IJ, Skates SJ, Macdonald N, Menon U, Rosenthal A, Davies AP, Woolas R, Yeyarayah A, Sibley K, Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-1210.
  20. Jacobs IJ, Skates SJ, Davies AP, Woolas RP, Yeyarayah A, Weidemann P, Sibley K, Oram DH. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355-1358.
  21. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65:221-225.
  22. Grover S, Quinn MA, Weidman P, Koh H, Robinson HP, Rome R, Cauchi M. Screening for ovarian cancer using serum CA 125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995;5:291-295.
  23. Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-1538.
  24. Bohm-Velez M, Mendelson E, Bree R, Finberg H, Fishman EK, Hricak H, Laing F, Sartoris D, Thurmond A, Goldstein S. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 Suppl:861-871.
  25. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, Bast RC Jr, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004-2010.
  26. Menon U, Jacobs IJ. Ovarian cancer screening in the general population. Ultrasound Obstet Gynecol 2000;15;350-353.
  27. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 2000;75:264-265.
  28. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, Kenemans P. CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999;9:117-124.
  29. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erisckson JR, Mills GB. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 2000;905:188-208.
  30. Xu Y, Shen Z, Wiper D, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynaecologic cancers. JAMA 1998;280:719-723.
  31. Roberts JA. Searching for a biomarker for ovarian cancer. JAMA 1998;280:739.
  32. Fishman DA, Cohen LS. Is transvaginal ultrasound effective for screening asymptomatic women for the detection of earlystage epithelial ovarian carcinoma? Gynecol Oncol 2000;77:347- 349.
  33. Bailey CL, Ueland FR, Land GL, DePriest PD, Gallion HH, Kryscio RJ, van Nagell JR. Malignant potential of small cystic ovarian tumors in postmenopausal women. Gynecol Oncol 1998;69:3-7.
  34. Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ, van Nagell JR. Ovarian volume related to age. Gynecol Oncol 2000;77:410-412.
  35. Menon U, Talaat A, Yeyarayah AR, Rosenthal AN, Macdonald ND, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA 125 elevation. Br J Cancer 1999;80:1644-1647.
  36. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Yeyarayah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening. Br J Obstet Gynaecol 2000;107:165-169.
  37. Law MR, Morris JK, Wald NJ. The importance of age in screening for cancer. J Med Screen 1999;6:16-20.
  38. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Huntigt) 1998;12:399-406.
  39. Pharoah PD, Stratton JF, Mackay J. Screening for breast and ovarian cancer: the relevance of family history. Br Med Bull 1998;54:823-838.
  40. Vasen HF, Haites NE, Evans DG, Stell CM, Moller P, Hodgson S, Eccles D, Morrison P, Stoppa Lyonet D, Chang-Claude J, Caligo M. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 european family cancer clinics. European Familial Breast cancer Collaborative Group. Eur J Cancer 1998;34:1922-1926.
  41. Karlan BY, Baldwin RL, Lopez-Luevanos E, Raffel LJ, Barbuto D, Narod S Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180:917-928.
  42. Bonilla-Musoles F, Raga F, Osborne NG. Three-dimensional ultrasound evaluation of ovarian masses. Gynecol Oncol 1995; 59:129-135.
  43. Chan L, Lin WM, Verpairojkit B, Hartman D, Reece EA. Evaluation of adnexal masses using three-dimensional ultrasonographic technology: preliminary report. J Ultrasound Med 1997;16:349-354.
  44. Kurjak A, Kupesic S, Breyer B, Sparac V, Jukic S. The assessment of ovarian tumor angiogenesis: what does three-dimensional power Doppler add? Ultrasound Obstet Gynecol 1998;12: 136-146.
  45. Kurjak A, Kupesic S, Sparac V, Kosuta D. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000;16:365- 371.
  46. Sassone MA, Timor-Tritsch IE, Artner A, Westhoff C, Waren B. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70-76.
  47. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved weighted scoring system. Am J Obstet Gynecol 1994;170:81-85.
  48. DePriest PD, Shenson D, Fried A, Hunter JE, Andrew SJ, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51:7-11.
  49. Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992;11:631-638.
  50. Kurjak A, Kupesic S, Anic T, Kosuta D. Three-dimensional ultrasound and power Doppler improve the diagnosis of ovarian lesions. Gynecol Oncol 2000;76:28-32.
  51. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82:40-48.
  52. Kupesic S, Kurjak A. Contrast-enhanced three-dimensional power Doppler sonography for the differentiation of adnexal masses. Obstet Gynecol 2000;96:452-458.
  53. Kurjak A, Kupesic S, Sparac V, Prka M, Bekavac I. The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler. Gynecol Oncol 2003;90:258-264.
  54. Kurjak A, Kupesic S, Sparac V, Bekavac I. Preoperative evaluation of pelvic tumors by Doppler and three-dimensional sonography. J Ultrasound Med 2001;20:829-840.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.